In a sign of weak demand, Novacea priced 6.25 million shares at $6.50, a sizeable 46% discount to its originally proposed $11 to $13 range. Bear Stearns, Cowen & Co., Pacific Growth and HSBC Corp. were the underwriters on the deal. The stock traded flat in...read more
Novacea, a developer of an analog of Vitamin D to treat prostate cancer, reduced its offering price to $6.50 from a range of $11 to $13. Bear Stearns and Cowen & Co. are the lead underwriters on the deal. Timing for the deal is day-to-day....read more
Novacea, a biopharmaceutical company focused on in-licensing and commercializing novel therapies for the treatment of cancer, filed its IPO pricing terms with the SEC on Friday. The company plans to offer 6.25 million shares at $11 to $13 each. At the $12...read more
Novacea, a biopharmaceutical company focused on in-licensing and commercializing novel therapies for the treatment of cancer, registered for an initial public offering Friday afternoon. Bear Stearns and Credit Suisse are listed as the joint book runners on the ...read more
Drug developer Novacea prices shares at $6.50
In a sign of weak demand, Novacea priced 6.25 million shares at $6.50, a sizeable 46% discount to its originally proposed $11 to $13 range. Bear Stearns, Cowen & Co., Pacific Growth and HSBC Corp. were the underwriters on the deal. The stock traded flat in...read more
Drug maker Novacea cuts proposed IPO price
Novacea, a developer of an analog of Vitamin D to treat prostate cancer, reduced its offering price to $6.50 from a range of $11 to $13. Bear Stearns and Cowen & Co. are the lead underwriters on the deal. Timing for the deal is day-to-day....read more
Cancer treatment firm Novacea sets IPO terms
Novacea, a biopharmaceutical company focused on in-licensing and commercializing novel therapies for the treatment of cancer, filed its IPO pricing terms with the SEC on Friday. The company plans to offer 6.25 million shares at $11 to $13 each. At the $12...read more
Biotech Novacea files for IPO
Novacea, a biopharmaceutical company focused on in-licensing and commercializing novel therapies for the treatment of cancer, registered for an initial public offering Friday afternoon. Bear Stearns and Credit Suisse are listed as the joint book runners on the ...read more